What biomarker testing is recommended for metastatic Melanoma

Biomarker Testing for Metastatic Melanoma

Based on the NCCN Guidelines for Patients: Melanoma (2025), here's what you should know about biomarker testing when melanoma has spread to distant sites (metastatic disease).

Key Biomarkers Tested

BRAF Mutation Testing This is the primary biomarker tested for metastatic melanoma. BRAF mutations are genetic changes that can cause normal skin cells to become cancerous. According to the NCCN Guidelines, testing for BRAF V600 mutations is important because:

• It directly influences which targeted therapy drugs your doctor might recommend
• BRAF mutations are found in a significant portion of melanomas
• If present, specific targeted drugs like dabrafenib/trametinib become treatment options

Other Gene Mutations The NCCN Guidelines note that testing for other genes that can harbor melanoma-predisposing mutations may also be needed, including:

• CDKN2A mutation (also called p16INK4A or MTS1) — the most common gene mutation for melanoma susceptibility

Why This Testing Matters

Biomarker testing helps your oncology team understand:

1. Which treatments will work best — Certain immunotherapy drugs work differently than targeted therapies
2. Your treatment options — BRAF-positive melanomas respond to targeted therapy approaches, while BRAF-negative melanomas typically use immunotherapy
3. Prognosis factors — Some biomarkers help predict how the cancer may respond to treatment

Questions to Ask Your Oncology Team

1. Have I been tested for BRAF mutations? If not, why not, and should I be?
2. What do my specific biomarker results mean for my treatment options?
3. Are there other genetic tests you recommend for my situation?
4. How will these results change my treatment plan?
5. Should my family members be tested for hereditary melanoma risk?

Important Context

According to the NCCN Guidelines, for metastatic melanoma, your doctor will determine the most appropriate treatment approach based on your complete clinical picture — including biomarker results, overall health, and other factors. The presence or absence of BRAF mutations is one important piece of information that guides whether you might benefit from targeted therapy versus immunotherapy approaches.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.